Please use this identifier to cite or link to this item: https://doi.org/10.1158/2159-8290.CD-17-0375
Title: VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma
Authors: Yao, X
Tan, J
Lim, K.J 
Koh, J
Ooi, W.F
Li, Z
Huang, D
Xing, M
Chan, Y.S
Qu, J.Z
Tay, S.T 
Wijaya, G
Lam, Y.N
Hong, J.H 
Lee-Lim, A.P
Guan, P
Ng, M.S.W
He, C.Z
Lin, J.S
Nandi, T
Qamra, A 
Xu, C 
Myint, S.S
Davies, J.O.J
Goh, J.Y
Loh, G
Tan, B.C
Rozen, S.G 
Yu, Q 
Tan, I.B.H 
Cheng, C.W.S 
Li, S 
Chang, K.T.E 
Tan, P.H
Silver, D.L 
Lezhava, A
Steger, G
Hughes, J.R
Teh, B.T 
Tan, P 
Keywords: chemokine receptor CXCR4
glucose transporter 1
hypoxia inducible factor 1alpha
vasculotropin A
von Hippel Lindau protein
basic helix loop helix transcription factor
DNA binding protein
endothelial PAS domain-containing protein 1
histone acetyltransferase PCAF
p300-CBP-associated factor
transcription factor
VHL protein, human
von Hippel Lindau protein
ZNF395 protein, human
Article
carcinogenesis
controlled study
DNA methylation
gene activation
gene expression
gene sequence
human
human cell
immunoblotting
immunoprecipitation
oncogene
polymerase chain reaction
principal component analysis
promoter region
protein deficiency
protein interaction
renal cell carcinoma
chromatin
enhancer region
gene expression regulation
genetics
mutation
oncogene
pathology
regulatory sequence
renal cell carcinoma
tumor cell line
Basic Helix-Loop-Helix Transcription Factors
Carcinogenesis
Carcinoma, Renal Cell
Cell Line, Tumor
Chromatin
DNA-Binding Proteins
Enhancer Elements, Genetic
Gene Expression Regulation, Neoplastic
Humans
Mutation
Oncogenes
p300-CBP Transcription Factors
Promoter Regions, Genetic
Regulatory Sequences, Nucleic Acid
Transcription Factors
Von Hippel-Lindau Tumor Suppressor Protein
Issue Date: 2017
Citation: Yao, X, Tan, J, Lim, K.J, Koh, J, Ooi, W.F, Li, Z, Huang, D, Xing, M, Chan, Y.S, Qu, J.Z, Tay, S.T, Wijaya, G, Lam, Y.N, Hong, J.H, Lee-Lim, A.P, Guan, P, Ng, M.S.W, He, C.Z, Lin, J.S, Nandi, T, Qamra, A, Xu, C, Myint, S.S, Davies, J.O.J, Goh, J.Y, Loh, G, Tan, B.C, Rozen, S.G, Yu, Q, Tan, I.B.H, Cheng, C.W.S, Li, S, Chang, K.T.E, Tan, P.H, Silver, D.L, Lezhava, A, Steger, G, Hughes, J.R, Teh, B.T, Tan, P (2017). VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discovery 7 (11) : 1284-1305. ScholarBank@NUS Repository. https://doi.org/10.1158/2159-8290.CD-17-0375
Abstract: Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel–Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivo. VHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α–HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 without overtly affecting preexisting promoter–enhancer interactions. Subtype-specific driver mutations such as VHL may thus propagate unique pathogenic dependencies in ccRCC by modulating epigenomic landscapes and cancer gene expression. SIGnIFICAnCE: Comprehensive epigenomic profiling of ccRCC establishes a compendium of somatically altered cis-regulatory elements, uncovering new potential targets including ZNF395, a ccRCC master regulator. Loss of VHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2α and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter–enhancer complexes. © 2017 American Association for Cancer Research.
Source Title: Cancer Discovery
URI: https://scholarbank.nus.edu.sg/handle/10635/176072
ISSN: 2159-8274
DOI: 10.1158/2159-8290.CD-17-0375
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1158_2159-8290_CD-17-0375.pdf5.77 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

39
checked on Nov 30, 2020

Page view(s)

21
checked on Dec 3, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.